International Journal of Biology Pharmacy and Allied Sciences,
Год журнала:
2023,
Номер
12(10 (SPECIAL ISSUE))
Опубликована: Окт. 12, 2023
This
systematic
review
highlights
the
potential
of
antioxidants
as
therapeutic
intervention
in
dry
eye
disease.Preclinical
reports
assessing
effect
plant
based
and
synthetic
against
disease
was
collected
from
online
electronic
databases
like
Scopus,
PubMed,
Science
direct,
DOAJ,
Jgate.The
protocol
registered
on
PROSPERO,
registration
no.CRD42023420934.The
followed
PRISMA
approach
for
including
all
were
appraised
risk
bias
using
SYRCLE's
RoB
tool.From
search
results
26
articles
met
inclusion
criteria
review.These
analyzed
rodent
species
strain
used,
which
improved
tear
volume,
restore
conjunctival
goblet
cells,
amelioration
inflammatory
cytokines
TNF-α,
IL-1β,
NLRP3
reduction
oxidative
stress.The
studies
reported
this
insinuates
target
their
mechanism
action
stress,
corneal
irregularity,
ocular
surface
inflammation
apoptosis
secretion.These
repots
compositely
suggest
that
can
ameliorate
negative
effects
improve
secretion
to
maintain
homeostasis.
Advances in Ophthalmology Practice and Research,
Год журнала:
2024,
Номер
4(1), С. 23 - 31
Опубликована: Янв. 29, 2024
Dry
eye
disease
(DED)
is
a
commonly
reported
ocular
complaint
that
has
garnered
significant
attention
in
recent
research.
The
global
occurrence
of
DED
ranges
from
5
%
to
50
%,
impacting
substantial
proportion
individuals
worldwide
with
increasing
frequency.
Although
topical
administration
remains
the
mainstream
drug
delivery
method
for
diseases,
it
suffers
drawbacks
such
as
low
bioavailability,
rapid
metabolism,
and
frequent
requirements.
Fortunately,
advancements
nanomedicine
offer
effective
solutions
address
aforementioned
issues
provide
assistance
treatment
DED.
considered
multifactorial
surface
tear
film,
which
integrity
film
function
structure
plays
crucial
role
maintaining
homeostasis
surface.
conventional
involves
utilization
artificial
products,
cyclosporin,
corticosteroids,
mucin
secretagogues,
nonsteroidal
anti-inflammatory
drugs.
Furthermore,
presently
field
study,
numerous
clinical
trials
underway
various
nanotherapeutics
including
nanoemulsions,
nanosuspensions,
liposomes,
micelles.
Notably,
some
these
innovative
nanoformulations
have
already
received
FDA
approval
novel
remedies
DED,
advancement
poised
enhanced
prospects
solve
shortcomings
existing
treatments
partially.
This
article
provides
an
overview
latest
treatment,
while
expected
witness
remarkable
breakthrough
shortly
development
nanomedicine,
bringing
promising
patients
suffering
conditions.
Advanced Functional Materials,
Год журнала:
2023,
Номер
34(6)
Опубликована: Дек. 6, 2023
Abstract
Dry
eye
disease
(DED)
is
a
widespread
ophthalmic
illness
that
inflicts
massive
economic
and
medical
burdens
on
society.
Although
oxidative
stress
closely
associated
with
the
onset
of
DED,
barely
any
quantities
antioxidants
are
clinically
available
owing
to
low
efficiency,
toxicity,
poor
bioavailability.
Cerium‐based
nanozymes
possess
promising
enzyme‐mimetic
activities
in
scavenging
reactive
oxygen
species
(ROS).
Moreover,
ultra‐small
metal–organic
frameworks
(MOFs)
have
potential
for
more
efficient
drug
delivery,
ROS
elimination,
therapeutic
efficacy.
However,
development
cerium‐based
MOFs
(Ce‐MOFs)
limited
small
minority
due
challenges
synthetic
process
stability.
By
simply
adjusting
raw
ingredients
concentrations,
three
types
Ce‐MOFs
distinct
particle
sizes
synthesized:
Ce‐MOF
1
(213
nm),
2
(36
3
(2
nm).
In
comparison,
obtained
exhibited
superior
antioxidant
capacity,
decreased
cytotoxicity,
excellent
ocular
penetration.
Therapeutically,
demonstrated
be
highly
alleviating
DED
by
suppressing
inflammation,
boosting
corneal
epithelial
repair,
facilitating
tear
secretion
recovery.
The
novel
may
serve
as
alternative
treatment
other
ROS‐related
disorders
when
combined
biocompatibility.
Nanomaterials,
Год журнала:
2024,
Номер
14(8), С. 669 - 669
Опубликована: Апрель 12, 2024
Dry
eye
disease
(DED)
incidence
is
continuously
growing,
positioning
it
to
become
an
emergent
health
issue
over
the
next
few
years.
Several
topical
treatments
are
commonly
used
treat
DED;
however,
reports
indicate
that
only
a
minor
proportion
of
drug
bioavailability
achieved
by
majority
drops
available
on
market.
In
this
context,
enhancing
ability
overcome
ocular
barriers
and
prolonging
its
residence
time
surface
represent
new
challenge
in
field
carrier
systems.
Therefore,
research
has
focused
development
multi-functional
nanosystems,
such
as
nanoemulsions,
liposomes,
dendrimers,
hydrogels,
other
nanosized
carriers.
These
systems
designed
improve
efficacy
and,
at
same
time,
require
fewer
daily
administrations,
with
potentially
reduced
side
effects.
This
review
summarizes
different
nanotechnologies
developed,
their
role
DED,
nanotechnology-based
eyedrops
currently
approved
for
DED
treatment.
Advanced Healthcare Materials,
Год журнала:
2024,
Номер
unknown
Опубликована: Май 13, 2024
Nanozymes,
characterized
by
their
nanoscale
size
and
enzyme-like
catalytic
activities,
exhibit
diverse
therapeutic
potentials,
including
anti-oxidative,
anti-inflammatory,
anti-microbial,
anti-angiogenic
effects.
These
properties
make
them
highly
valuable
in
nanomedicine,
particularly
ocular
therapy,
bypassing
the
need
for
systemic
delivery.
Nanozymes
show
significant
promise
tackling
multi-factored
diseases,
those
influenced
oxidation
inflammation,
like
dry
eye
disease,
age-related
macular
degeneration.
Their
small
size,
coupled
with
ease
of
modification
integration
into
soft
materials,
facilitates
effective
penetration
barriers,
thereby
enabling
targeted
or
prolonged
therapy
within
eye.
This
review
is
dedicated
to
exploring
diseases
that
are
intricately
linked
shedding
light
on
role
nanozymes
managing
these
conditions.
Additionally,
recent
studies
elucidating
advanced
applications
therapeutics,
along
materials
disease
management,
discussed.
Finally,
this
outlines
directions
future
investigations
aimed
at
bridging
gap
between
nanozyme
research
clinical
applications.
ACS Applied Materials & Interfaces,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 8, 2025
Diabetes
mellitus
(DM)
induced
mitochondrial
oxidative
stress
(OS)
can
lead
to
severe
injury
of
dental
pulp.
The
cerium
oxide
nanoparticles
(CNP)
have
been
proven
excellent
antioxidative
activity.
However,
whether
CNP
relieve
pulp
damage
caused
by
DM
and
the
underlying
mechanisms
remain
unclear.
In
this
study,
we
modified
ceria
with
hyaluronic
acid
prepare
nanoceria
good
biocompatibility,
water
solubility,
stability,
namely,
HACNP
(hyaluronic
nanoparticles).
We
demonstrated
protective
effect
on
diabetic
OS-induced
apoptosis
in
pulp-like
cells.
As
far
as
mechanism
action
was
concerned,
glucose
oxidase
(GO)
treatment
promoted
activation
phosphoglycerate
mutase
family
5
(PGAM5)
leading
abnormalities
an
odontoblast-like
cell
line
(mDPC6T).
Knockdown
or
overexpression
PGAM5
further
validate
these
results.
Meanwhile,
remitted
GO-related
toxicity
via
down-regulating
expression,
whereas
abolished
beneficial
HACNP.
Furthermore,
constructed
animal
research
model
injury,
also
confirmed
that
alleviated
decreased
expression
level
tissue.
conclusion,
results
revealed
played
a
role
diabetes-associated
through
targeting
PGAM5-mediated
pathway,
providing
idea
method
for
prevention
diabetes-induced
damage.
Advanced Healthcare Materials,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 19, 2025
Abstract
Dry
eye
disease
(DED)
is
a
multifaceted
ocular
surface
disorder
that
significantly
impacts
patients’
daily
lives
and
imposes
substantial
economic
burden
on
society.
Oxidative
stress,
induced
by
the
overproduction
of
reactive
oxygen
species
(ROS),
critical
factor
perpetuating
inflammatory
cycle
in
DED.
Effectively
scavenging
ROS
essential
to
impede
progression
In
this
study,
boronophenylalanine‐
containing
polydopamine
(PDA‐PBA)
nanoparticles
are
developed
loaded
with
melatonin
(MT),
which
blended
poly(vinyl
alcohol)
(PVA)
create
drops
PVA/
PDA‐PBA@MT
(PPP@MT).
vitro
vivo
studies
demonstrate
PPP@MT
exhibits
dual
functionalities
reducing
production
downregulating
pathways,
thereby
preserving
mitochondrial
integrity
further
inhibiting
programmed
cell
death.
Following
treatment,
tear
secretion,
corneal
structure,
number
goblet
cells
markedly
restored
mouse
model
dry
eye,
indicating
therapeutic
efficacy
agent.
Collectively,
PPP@MT,
characterized
minimal
side
effects
favorable
bioavailability,
offers
promising
insights
for
management
DED
other
ROS‐mediated
disorders.